Singapore wants co-investors to pump $112M into deep tech startups

Singapore is seeking co-investors from the private sector with the goal to plow up to SG$150 million into its early-stage, deep tech startup community. It hopes to identify 10 to 15 such partners and target startups in three key sectors including health and biomedical sciences. 

Led by Enterprise Singapore’s investment arm Seeds Capital, the initiative will tap funds from the Startup SG Equity scheme, under which the government may invest in funds or work with qualified third-party investors to make direct co-investments into eligible startups.

With the new call-for-partnership, Seeds said in a statement Thursday it aimed to refresh and diversity its current pool of 30 co-investment partners across the three deep tech sectors, including advanced manufacturing and engineering as well as urban solutions and sustainability. These market segments were aligned with the country’s Research, Innovation, and Enterprise 2020 (RIE2020) Technology Domains, which aimed to boost Singapore’s research capabilities and

Read More

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Control-IQ™ technology. Control-IQ technology is an advanced hybrid closed-loop feature designed to help increase time in range (3.9-10 mmol/L)1 and deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. The system integrates with Dexcom G6 continuous glucose monitoring (CGM), which requires no fingersticks for calibration or diabetes treatment decisions.2,3,4

All in-warranty t:slim X2 pump users in Canada will have the option to add Control-IQ technology to their existing pump beginning in March 2021 via remote software update. The update will be free of charge through December 31, 2021.5 Tandem expects to begin shipping t:slim X2 insulin pumps with Control-IQ technology in Canada in the first quarter of next year.

Read More

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology – Press Release

SAN DIEGO–(Business Wire)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Control-IQ™ technology. Control-IQ technology is an advanced hybrid closed-loop feature designed to help increase time in range (3.9-10 mmol/L)1 and deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. The system integrates with Dexcom G6 continuous glucose monitoring (CGM), which requires no fingersticks for calibration or diabetes treatment decisions.2,3,4

All in-warranty t:slim X2 pump users in Canada will have the option to add Control-IQ technology to their existing pump beginning in March 2021 via remote software update. The update will be free of charge through December 31, 2021.5 Tandem expects to begin shipping t:slim X2 insulin pumps with Control-IQ technology in Canada in the first quarter of next year. The company

Read More

Biofriendly protocells pump up blood vessels — ScienceDaily

An international team comprising researchers from the University of Bristol, and Hunan and Central South Universities in China, have prepared biocompatible protocells that generate nitric oxide gas — a known reagent for blood vessel dilation — that when placed inside blood vessels expand the biological tissue.

In a new study published today in Nature Chemistry, Professor Stephen Mann and Dr Mei Li from Bristol’s School of Chemistry, together with Associate Professor Jianbo Liu and colleagues at Hunan University and Central South University in China, prepared synthetic protocells coated in red blood cell fragments for use as nitric oxide generating bio-bots within blood vessels.

Coating the protocells led to increased levels of biocompatibility and longer blood circulation times. Critically, the team trapped an enzyme inside the protocells which, in the presence of glucose, produced hydrogen peroxide. This was then used by haemoglobin in the protocell membrane to degrade the drug

Read More

Nikkiso Cryo Pump Technology Part of Excelerate Energy’s Record Breaking FSRU Send-Out Capacity

TEMECULA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to be the primary pump supplier for Excelerate Energy’s floating storage and regasification units (FSRUs).

Excelerate Energy’s Floating Storage & Regasification Unit (FSRU “Experience”) recently reached an industry record-breaking send-out capacity of 1.06 billion cubic feet (bcf) of natural gas. Nikkiso Cryo’s suction vessel mounted vertical submerged motor centrifugal pumps were used on the FSRU.

The product is designed so the pump and suction vessel become an integral part of the piping system with external suction and discharge connections. The pump is mounted to the top, or head plate, of the vessel such that the pump, motor and fluid product are totally contained within the pressure vessel.

The suction vessel also serves to allow entrained vapors to be separated and go through the

Read More

New heart pump technology helps aid recovery in heart attack patients



a man and woman riding on the back of a bicycle: John Hays (left), with his wife, Gwen, suffered a heart attack Aug. 25 and underwent surgery six days later. Doctors performed the procedure with the new Impella 5.5 technology, which enables heart recovery in patients whose hearts are too weak to effectively pump blood.


© [Courtesy of Palm Beach Gardens Medical Center]
John Hays (left), with his wife, Gwen, suffered a heart attack Aug. 25 and underwent surgery six days later. Doctors performed the procedure with the new Impella 5.5 technology, which enables heart recovery in patients whose hearts are too weak to effectively pump blood.

PALM BEACH GARDENS – John Hays had his first heart attack at age 35.

He had his second three decades later while mountain biking in Dyer Park.

A former triathlete and grandfather of two, the 65-year-old North Palm Beach resident went home before being transported to nearby Palm Beach Gardens Medical Center, where doctors saved his life by using cutting-edge technology called an Impella 5.5 with SmartAssist heart pump.

More: Q&A: Palm Beach Gardens doctor reveals what he’s learned in six months of COVID-19 care

The device, which is temporarily implanted in a patient’s heart during surgery,

Read More